Article
Biochemistry & Molecular Biology
Ayse Bassez, Hanne Vos, Laurien Van Dyck, Giuseppe Floris, Ingrid Arijs, Christine Desmedt, Bram Boeckx, Marlies Vanden Bempt, Ines Nevelsteen, Kathleen Lambein, Kevin Punie, Patrick Neven, Abhishek D. Garg, Hans Wildiers, Junbin Qian, Ann Smeets, Diether Lambrechts
Summary: The study found that in breast cancer patients, anti-PD1 treatment can lead to clonal expansion of PD1-expressing T cells in a subset of tumors, regardless of tumor subtype. The expansion mainly involves CD8(+) T cells and CD4(+) T cells with distinct immune cell characteristics.
Article
Immunology
Felix Bayerl, Philippa Meiser, Sainitin Donakonda, Anna Hirschberger, Sebastian B. Lacher, Anna-Marie Pedde, Chris D. Hermann, Anais Elewaut, Moritz Knolle, Lukas Ramsauer, Thomas J. Rudolph, Simon Grassmann, Rupert Oellinger, Nicole Kirchhammer, Marcel Trefny, Martina Anton, Dirk Wohlleber, Bastian Hoechst, Anne Zaremba, Achim Krueger, Roland Rad, Anna C. Obenauf, Dirk Schadendorf, Alfred Zippelius, Veit R. Buchholz, Barbara U. Schraml, Jan P. Boettcher
Summary: Tumor-derived prostaglandin E2 (PGE2) induces dysfunction in conventional dendritic cells (cDC1s), impairing anti-cancer CD8+ T cell responses, and this dysfunction is associated with poor prognosis in cancer patients.
Review
Immunology
Erin E. Peterson, Kevin C. Barry
Summary: The intercellular cross-talk between NK cells and cDC1s plays a crucial role in immune responses to cancer, impacting the efficacy of certain immunotherapies and overall survival rates for patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
Xingzhe Ma, Liuling Xiao, Lintao Liu, Lingqun Ye, Pan Su, Enguang Bi, Qiang Wang, Maojie Yang, Jianfei Qian, Qing Yi
Summary: Understanding the mechanisms of how T cells become dysfunctional in a tumor microenvironment is crucial for cancer immunotherapy. This study found that CD36 expression in tumor-infiltrating CD8(+) T cells, induced by TME cholesterol, is associated with tumor progression and poor survival, and that genetic ablation of Cd36 in these T cells leads to enhanced tumor eradication. Targeting CD36 or inhibiting ferroptosis could restore T cell function and enhance antitumor efficacy, especially in combination with anti-PD-1 antibodies.
Article
Oncology
Li Guan, Dhanya K. Nambiar, Hongbin Cao, Vignesh Viswanathan, Shirley Kwok, Angela B. Hui, Yuan Hou, Rachel Hildebrand, Rie von Eyben, Brittany J. Holmes, Junfei Zhao, Christina S. Kong, Nathan Wamsley, Weiruo Zhang, Michael B. Major, Seung W. Seol, John B. Sunwoo, D. Neil Hayes, Maximilian Diehn, Quynh-Thu Le
Summary: Radiotherapy is a primary treatment for head and neck squamous cell carcinoma (HNSCC), but there is currently no reliable biomarker for predicting radioresistance. This study found that mutations in the NFE2L2 gene are associated with higher rates of locoregional failure in HNSCC patients treated with surgery and (chemo)radiotherapy. NFE2L2 mutations lead to radioresistance through Nrf2 activation, but this can be overcome by the glutaminase inhibitor CB-839.
Article
Oncology
Chi-Ping Huang, Hsin-Ling Lu, Chih-Rong Shyr
Summary: Intratumoral xenogeneic urothelial cell (XUC) immunotherapy can effectively suppress the growth of bladder cancer and its efficacy is enhanced when combined with chemotherapy. This treatment induces immune cell infiltration and activation, leading to both local and systemic anti-tumor effects. Therefore, intratumoral XUC therapy holds potential as a local treatment for advanced bladder cancer.
AMERICAN JOURNAL OF CANCER RESEARCH
(2023)
Review
Pharmacology & Pharmacy
Yeye Hu, Wei Zhang, Xiaozhong Chu, Aoran Wang, Ziliang He, Chuan-Ling Si, Weicheng Hu
Summary: This paper reviews and compares DC surface receptors and their specific coupling natural ligands and antibodies, describes reaction mechanisms, and demonstrates the synergistic effects of immune adjuvants. Moreover, extracellular-targeting antigen-delivery strategies and intracellular stimulus responses are reviewed to promote the rational design of polymer delivery systems.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Article
Oncology
Shengchen Lin, Yunzhan Li, Dezhen Wang, Chongbiao Huang, David Marino, Oana Bollt, Chaodong Wu, Matthew D. Taylor, Wei Li, Gina M. DeNicola, Jihui Hao, Pankaj K. Singh, Shengyu Yang
Summary: Fascin, a pro-metastatic actin-bundling protein, promotes cancer cell migration and invasion by increasing glycolysis in lung cancer through activation of yes-associated protein 1 (YAP1). The fascin-YAP1-PFKFB3 axis is likely conserved across different types of cancers, and pharmacological inhibitors of fascin may be used to reprogram cancer metabolism in lung and potentially other cancers with fascin upregulation.
Article
Multidisciplinary Sciences
Tho-Alfakar Al-Aubodah, Lamine Aoudjit, Giuseppe Pascale, Maneka A. Perinpanayagam, David Langlais, Martin Bitzan, Susan M. Samuel, Ciriaco A. Piccirillo, Tomoko Takano
Summary: Using single-cell RNA sequencing, the authors identify an extrafollicular B cell response in the blood samples of children with active INS, providing important insights into the B cell subsets in this disease.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Hong Wu, Xuefeng Leng, Qianshi Liu, Tianqin Mao, Tao Jiang, Yiqiang Liu, Feifei Li, Chenhui Cao, Jun Fan, Liang Chen, Yaqi Chen, Quan Yao, Shun Lu, Renchuan Liang, Lanlin Hu, Mingxin Liu, Yejian Wan, Zhaoshen Li, Jun Peng, Qiyu Luo, Hang Zhou, Jun Yin, Ke Xu, Mei Lan, Xinhao Peng, Haitao Lan, Gang Li, Yongtao Han, Xia Zhang, Zhi-Xiong Jim Xiao, Jinyi Lang, Guihua Wang, Chuan Xu
Summary: Analysis of intratumoral microbiota in patients with esophageal cancer reveals a microbiota signature that is associated with chemoimmunotherapy response, showing that Streptococcus stimulates CD8+ T-cell infiltration and induces a favorable response. These findings suggest the potential clinical utility of intratumoral microbiota for cancer immunotherapy.
Article
Oncology
Gregg L. Semenza
Summary: This review summarizes recent reports on hypoxia-induced mechanisms of immune evasion in various types of cancer. These studies suggest novel therapeutic approaches to improve anti-tumor immunity and increase responses to immunotherapy.
SEMINARS IN CANCER BIOLOGY
(2023)
Article
Immunology
Adam L. Burrack, Meagan R. Rollins, Ellen J. Spartz, Taylor D. Mesojednik, Zoe C. Schmiechen, Jackson F. Raynor, Iris X. Wang, Ross M. Kedl, Ingunn M. Stromnes
Summary: Pancreatic cancer is resistant to immunotherapy due to T cell exhaustion, but using a specific immune treatment strategy can overcome this and lead to tumor regression.
JOURNAL OF IMMUNOLOGY
(2021)
Article
Oncology
Luis Alejandro Zuniga, Torben Lessmann, Karan Uppal, Nicola Bisek, Enping Hong, Caroline E. Rasmussen, Jens-Jakob Karlsson, Joachim Zettler, Lars Holten-Andersen, Kathy Bang, Dhruv Thakar, Yu-Chi Lee, Salomon Martinez, Simran Singh Sabharwal, Sebastian Stark, Frank Faltinger, Oliver Kracker, Samuel Weisbrod, Robin Mueller, Tobias Voigt, Kornelia Bigott, Mohammad Tabrizifard, Vibeke Miller Breinholt, Amer M. Mirza, David B. Rosen, Kennett Sprogoe, Juha Punnonen
Summary: The TransCon TLR7/8 Agonist has been developed as a sustained-release prodrug of resiquimod, showing potent anti-tumor effects and activation of immune cells in the tumor microenvironment when used alone or in combination with systemic immunotherapy. This study highlights the potential of TransCon TLR7/8 Agonist as a novel intratumoral TLR agonist for cancer therapy.
CANCER CELL INTERNATIONAL
(2022)
Article
Chemistry, Multidisciplinary
Hao Fu, Lizhu Chen, Wenming Fang, Ping Hu, Jianlin Shi
Summary: Immunotherapy has great potential in solid tumor therapy, but current outcomes are unsatisfactory. This study proposes a novel strategy using a magnetic nanocatlytic medicine to stimulate innate and adaptive immunity while enhancing immune cell infiltration, leading to improved immunotherapy for solid tumors.
Article
Multidisciplinary Sciences
Chuansheng Guo, Zhiyuan You, Hao Shi, Yu Sun, Xingrong Du, Gustavo Palacios, Cliff Guy, Sujing Yuan, Nicole M. M. Chapman, Seon Ah Lim, Xiang Sun, Jordy Saravia, Sherri Rankin, Yogesh Dhungana, Hongbo Chi
Summary: Cancer cells evade T cell-mediated killing through unknown mechanisms. Dendritic cells, especially type-1 conventional DCs, play a crucial role in T cell priming and therapeutic efficacy against tumors. The function of dendritic cells is orchestrated by pattern recognition receptors, but other signals involved are not fully defined. Nutrients have been identified as emerging mediators of adaptive immunity, but their impact on dendritic cell function and communication between innate and adaptive immune cells is still unclear.
Article
Multidisciplinary Sciences
Ke Xu, Na Yin, Min Peng, Efstathios G. Stamatiades, Amy Shyu, Peng Li, Xian Zhang, Mytrang H. Do, Zhaoquan Wang, Kristelle J. Capistrano, Chun Chou, Andrew G. Levine, Alexander Y. Rudensky, Ming O. Li
Summary: The passage discusses the impact of infection on T cell immune response, highlighting the crucial role of glycolytic enzyme LDHA in regulating the PI3K-Akt-Foxo1 signaling pathway, a mechanism that serves as a key factor in controlling T cell immunity.
Article
Immunology
Ke Xu, Na Yin, Min Peng, Efstathios G. Stamatiades, Sagar Chhangawala, Amy Shyu, Peng Li, Xian Zhang, Mytrang H. Do, Kristelle J. Capistrano, Chun Chou, Christina S. Leslie, Ming O. Li
Summary: The Warburg effect, characterized by aerobic glycolysis, is an important metabolic feature of effector T cells, driving their responses through ATP production via LDHA. LDHA deficiency impairs T cell activation, proliferation, and differentiation by disrupting the PI3K-Akt-Foxo1 signaling pathway. This study highlights the crucial role of Warburg metabolism in regulating effector T cell responses.
Article
Biochemistry & Molecular Biology
Che-Chia Hsu, Xian Zhang, Guihua Wang, Weina Zhang, Zhen Cai, Bo-Syong Pan, Haiwei Gu, Chuan Xu, Guoxiang Jin, Xiangshang Xu, Rajesh Kumar Manne, Yan Jin, Wei Yan, Jingwei Shao, Tingjin Chen, Emily Lin, Amit Ketkar, Robert Eoff, Zhi-Gang Xu, Zhong-Zhu Chen, Hong-Yu Li, Hui-Kuan Lin
Summary: Inositol is a critical metabolite that directly restricts AMPK-dependent mitochondrial fission. Changes in inositol levels affect AMPK activation and mitochondrial fission. Metabolic stress or mitochondrial damage can cause a decline in inositol levels, leading to AMPK-dependent mitochondrial fission.
Review
Oncology
Ziqi Yu, Mei Song, Lotfi Chouchane, Xiaojing Ma
Summary: Metastasis remains the leading cause of death in breast cancer patients worldwide, with genomic profiling methods revolutionizing our understanding of this complex process. There is a lack of accurate prognostic indicators and effective treatments for metastasis, highlighting the importance of recent advancements in functional genomic analysis for potential prognostic and therapeutic implications.
Article
Oncology
Xiang Chen, Seung Koo Lee, Mei Song, Tiantian Zhang, Myung Shin Han, Yao-Tseng Chen, Zhengming Chen, Xiaojing Ma, Ching-Hsuan Tung, Yi-Chieh Nancy Du
Summary: Researchers developed a RHAMMB-targeting nanoparticle to deliver siRNA and KLA peptide into PNET cells, achieving a synergistic killing effect and significantly reducing tumor burden in mice with RHAMMB-positive PNETs.
MOLECULAR THERAPY-ONCOLYTICS
(2021)
Article
Cell Biology
Meixi Peng, Jun Ren, Yipei Jing, Xueke Jiang, Qiaoling Xiao, Junpeng Huang, Yonghong Tao, Li Lei, Xin Wang, Zailin Yang, Zesong Yang, Qian Zhan, Can Lin, Guoxiang Jin, Xian Zhang, Ling Zhang
Summary: In patients with NPM1-mutated AML, leukemic cells release miR-19a-3p through sEVs to suppress the immune function of CD8+ T cells by inhibiting creatine import mediated by SLC6A8. This immune evasion mechanism may serve as a promising therapeutic target for NPM1-mutated AML.
JOURNAL OF EXTRACELLULAR VESICLES
(2021)
Article
Multidisciplinary Sciences
Chun Chou, Xian Zhang, Chirag Krishna, Briana G. Nixon, Saida Dadi, Kristelle J. Capistrano, Emily R. Kansler, Miranda Steele, Jian Han, Amy Shyu, Jing Zhang, Efstathios G. Stamatiades, Ming Liu, Shun Li, Mytrang H. Do, Chaucie Edwards, Davina S. Kang, Chin-Tung Chen, Iris H. Wei, Emmanouil P. Pappou, Martin R. Weiser, J. Garcia-Aguilar, J. Joshua Smith, Christina S. Leslie, Ming O. Li
Summary: A new class of tumor-infiltrating T cells (ILTCKs) has been identified, which are alpha beta T cell receptor (TCR)-positive and express FCER1G, with high cytotoxic potential. ILTCKs react broadly to unmutated self-antigens, arise from distinct thymic progenitors following early encounter with cognate antigens, and are continuously replenished by thymic progenitors during tumor progression. ILTCKs' expansion and effector differentiation depend on interleukin-15 (IL-15) expression in cancer cells, and inducible activation of IL-15 signaling suppresses tumor growth. This distinguishes ILTCKs from conventional cytotoxic T cells.
Article
Immunology
Emily R. Kansler, Saida Dadi, Chirag Krishna, Briana G. Nixon, Efstathios G. Stamatiades, Ming Liu, Fengshen Kuo, Jing Zhang, Xian Zhang, Kristelle Capistrano, Kyle A. Blum, Kate Weiss, Ross M. Kedl, Guangwei Cui, Koichi Ikuta, Timothy A. Chan, Christina S. Leslie, A. Ari Hakimi, Ming O. Li
Summary: This study reveals an innate immune surveillance response mediated by cytotoxic ILC1 sensing of cancer cell-expressed IL-15, which is associated with patient survival and contributes to tumor suppression.
Article
Cell Biology
Gang Xiang, Shuxuan Wang, Ling Chen, Mei Song, Xiaoxu Song, Huan Wang, Pengbo Zhou, Xiaojing Ma, Jing Yu
Summary: This study reveals that CDC73, a substrate of UBR5, plays a crucial role in inhibiting tumor growth and metastasis in triple-negative breast cancer (TNBC) and is negatively associated with breast cancer progression. Destabilizing CDC73 through polyubiquitination provides a potential approach to suppress the pro-tumor activities of UBR5.
CELL DEATH & DISEASE
(2022)
Article
Immunology
Xiaoxue Wu, Shuting Huang, Weiling He, Mei Song
Summary: HER2 is a therapeutic target in various types of cancer with HER2 overexpression or genomic alterations. Trastuzumab, a humanized monoclonal antibody targeting HER2, has improved the clinical outcomes of HER2-positive patients. However, resistance to trastuzumab poses a challenge, and this review explores the mechanisms of resistance and discusses potential strategies for improving patient outcomes through rational combinations.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Jialing Gao, Xiaoxue Wu, Shuting Huang, Ziyi Zhao, Weiling He, Mei Song
Summary: This article provides an overview of copper homeostasis and its associated pathological disorders, especially copper metabolism in carcinogenesis. It summarizes the current knowledge of the tumor suppressive mechanisms of elesclomol, with emphasis on cuproptosis. Finally, strategies for better application of elesclomol in cancer therapy are discussed.
Article
Medicine, Research & Experimental
Bingbing Wu, Mei Song, Qun Dong, Gang Xiang, Jing Li, Xiaojing Ma, Fang Wei
Summary: This study identifies UBR5 as a key regulator of PD-L1 transcription induced by IFN-gamma and elucidates the underlying molecular mechanisms, providing a strong rationale for combination cancer immunotherapies targeting UBR5 and PD-L1.
Article
Medicine, Research & Experimental
Chuan Xu, Guoxiang Jin, Hong Wu, Wei Cui, Yu-Hui Wang, Rajesh Kumar Manne, Guihua Wang, Weina Zhang, Xian Zhang, Fei Han, Zhen Cai, Bo-Syong Pan, Che-Chia Hsu, Yiqiang Liu, Anmei Zhang, Jie Long, Hongbo Zou, Shuang Wang, Xiaodan Ma, Jinling Duan, Bin Wang, Weihui Liu, Haitao Lan, Qing Xiong, Gang Xue, Zhongzhu Chen, Zhigang Xu, Mark E. Furth, Sarah Haigh Molina, Yong Lu, Dan Xie, Xiu-Wu Bian, Hui-Kuan Lin
Summary: Signal regulatory protein gamma (SIRP gamma) determines the properties and immune evasiveness of cancer stem-like cells (CSLCs) in a small population of lung adenocarcinoma (LUAD) cancer cells. SIRP gamma activates the Hippo/YAP signaling pathway to release cytokines and stimulate CD47 expression in tumor cells, inhibiting their phagocytosis. Targeting SIRP gamma can inhibit CSLC phenotypes and promote tumor phagocytosis, making it an immune and CSLC-targeting strategy for lung cancer therapy.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
